Chlamydia infections can contribute to heart problems, though the risk depends on which type of chlamydia is involved and how the body responds. There are three species of chlamydia that affect humans, and each one has a different relationship with heart disease. The sexually transmitted infection (Chlamydia trachomatis) poses a small but real cardiac risk, while the respiratory form (Chlamydia pneumoniae) has been more extensively linked to arterial disease. A third species, Chlamydia psittaci, caught from birds, can directly inflame the heart muscle.
Three Types of Chlamydia, Three Paths to Heart Trouble
When most people hear “chlamydia,” they think of the sexually transmitted infection caused by Chlamydia trachomatis. That’s just one of three species that infect humans. Chlamydia pneumoniae spreads through the air like a common cold and infects the lungs. Most people catch it at some point in their lives, often without realizing it. Chlamydia psittaci comes from contact with infected birds and causes a disease called psittacosis.
Each of these can affect the heart through different mechanisms. C. pneumoniae has drawn the most research attention because of its potential role in atherosclerosis, the buildup of fatty plaques in arteries that leads to heart attacks and strokes. C. trachomatis has been found in diseased heart valves and arterial tissue. C. psittaci can cause acute inflammation of the heart muscle itself.
How Chlamydia Triggers Artery Damage
The strongest evidence linking chlamydia to heart disease involves C. pneumoniae and atherosclerosis. The bacteria don’t just stay in your lungs. They can hitch a ride inside immune cells called monocytes, which carry them through the bloodstream directly to artery walls. Once there, the organisms slip through the lining of the artery and set up a local infection, driving chronic inflammation that accelerates plaque formation.
This inflammation shows up in blood tests. People infected with C. pneumoniae tend to have elevated levels of C-reactive protein (CRP), a marker doctors use to assess cardiovascular risk. They also show higher levels of IL-6, a signaling molecule that drives systemic inflammation. Both of these markers are independently associated with heart attacks and strokes, meaning the infection may amplify existing cardiovascular risk factors.
The bacteria also appear to interact with cholesterol in a damaging way. One proposed mechanism is that the infection promotes the oxidation of LDL cholesterol, the “bad” cholesterol. Oxidized LDL is far more likely to be absorbed into artery walls and contribute to plaque buildup than normal LDL. This could help explain why some people with only moderately high cholesterol still develop significant arterial disease.
The Autoimmune Connection
One of the most striking findings involves a phenomenon called molecular mimicry. Researchers at the University of Toronto discovered that a surface protein on chlamydia bacteria closely resembles a protein found in heart muscle tissue called myosin. When the immune system recognizes the bacteria as foreign and mounts an attack, it can accidentally begin attacking the body’s own heart muscle because the two proteins look so similar.
In laboratory experiments, when chlamydia proteins were injected into mice, up to 88% of them developed inflammatory heart disease. The same immune cells that targeted the bacterial protein also targeted heart myosin, confirming that the immune system was confusing the two. This autoimmune reaction offers a direct biological explanation for how a common infection could lead to heart inflammation without the bacteria ever reaching the heart itself.
Infections of the Heart Valves and Muscle
In rare cases, chlamydia bacteria physically infect heart tissue. Endocarditis, an infection of the heart valves, has been documented with both C. trachomatis and C. pneumoniae. These cases are particularly tricky to diagnose because standard blood cultures come back negative. The bacteria don’t grow well in the culture bottles hospitals typically use, so doctors may initially rule out a heart infection based on those negative results.
Diagnosis usually requires specialized antibody testing. Doctors look for very high levels of specific antibodies using a technique called microimmunofluorescence, where titers above 1:512 raise strong suspicion. Confirmation often comes only after valve tissue is surgically removed and tested using DNA-based methods like PCR. In one documented case, a patient’s C. pneumoniae endocarditis was only confirmed after molecular testing of valve tissue that had been taken out during surgery.
Chlamydia psittaci poses a more acute threat. In a reported case, a 30-year-old man with no medical history developed chest pain, cough, and fever after occupational exposure to birds. His troponin level, a marker of heart muscle damage, was more than 70 times the normal upper limit, and his CRP was over 35 times normal. Imaging confirmed both pneumonia and acute myocarditis, or inflammation of the heart muscle. He recovered fully after antibiotic treatment and three months of anti-inflammatory therapy.
How Much Does Chlamydia Raise Heart Risk?
The numbers are more modest than early research suggested. A large meta-analysis combining 15 prospective studies with over 3,100 heart disease cases found that people with antibodies to C. pneumoniae had a combined odds ratio of 1.15 for coronary heart disease. That translates to roughly a 15% higher risk, but the result was not statistically significant, meaning it could be due to chance. Individual studies have shown higher numbers. One found an odds ratio of 1.66, suggesting a 66% increased risk, but after adjusting for smoking and socioeconomic factors, the association dropped to 1.22 and lost statistical significance.
This pattern suggests that much of the apparent link between chlamydia and heart disease may be explained by shared risk factors. People more likely to be exposed to C. pneumoniae infections, through crowded living conditions or smoking, are also more likely to develop heart disease for other reasons. That doesn’t mean the infection plays no role, but it makes it difficult to isolate the bacteria’s independent contribution.
Antibiotics Don’t Seem to Help
If chlamydia were a major driver of heart disease, treating it should reduce heart attacks. A landmark trial published in the New England Journal of Medicine tested exactly this. Over 4,100 patients who had recently been hospitalized for a heart event were randomly assigned to receive either a potent antibiotic effective against C. pneumoniae or a placebo. Treatment continued for an average of two years.
The results were clear: antibiotic treatment made no difference. Heart events occurred in 23.7% of the antibiotic group and 25.1% of the placebo group, a gap easily attributable to chance. Even among patients with elevated antibody levels to C. pneumoniae or high CRP levels, antibiotics provided no benefit. This trial, along with several similar ones, effectively ended the hope that treating chlamydia infections could prevent heart disease.
The Long Timeline of Damage
Both C. pneumoniae infection and atherosclerosis begin surprisingly early in life. Studies of children’s arteries at autopsy have found fatty streaks, the earliest signs of plaque formation, in 50% of children aged 2 to 15. By the late 30s, 69% of people show raised fibrous plaques in their coronary arteries. Meanwhile, C. pneumoniae infection rates are highest in children aged 5 to 14, with annual rates of new infection reaching 9.2% in the 5 to 9 age group. Many of these infections produce no symptoms at all.
The parallel timing is suggestive. Both processes start in childhood, progress silently over decades, and become clinically apparent in middle age. Using ultrasound imaging of otherwise healthy heart donors, researchers found coronary artery thickening in 17% of people under 20, rising steadily to 85% of those over 50. Whether repeated, asymptomatic chlamydia infections throughout life contribute meaningfully to this progression remains an open question, but the overlap in timing and the biological mechanisms described above make it plausible that the bacteria play at least a supporting role in a process driven primarily by cholesterol, blood pressure, and other traditional risk factors.